2026-01-22 - Analysis Report
# REGN Financial Report


## Company Overview
Regeneron Pharmaceuticals is a biotechnology company that develops and commercializes pharmaceuticals and biologics.


## Stock Comparison
We compared the return rate of REGN with the return rate of S&P 500 (VOO):
* **Review Stock (REGN):** Cumulative return: 28.13%
* **Comparison Stock (VOO):** Cumulative return: 91.55%
* **Divergence:** -67.90 (max: 31.70, min: -93.00, current: -67.90, relative divergence: 20.10%)

## Stock Performance Analysis (Yearly Data)
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | -14.0% | 22.4% | -19.0% | 1.2 | 39.6B |
| 2017-2019  | -3.0% | 28.6% | -21.0% | 1.0 | 39.8B |
| 2018-2020  | 2.0% | 28.6% | -19.0% | 0.7 | 51.2B |
| 2019-2021  | 29.0% | 28.6% | -15.0% | 0.6 | 66.9B |
| 2020-2022  | 55.0% | 14.4% | 56.0% | 0.6 | 76.5B |
| 2021-2023  | 46.0% | 14.4% | 45.0% | 0.6 | 93.1B |
| 2022-2024  | -7.0% | 30.9% | -26.0% | 0.6 | 75.5B |
| 2023-2025  | -4.0% | 45.4% | -66.0% | 0.6 | 81.8B |

## Recent Stock Price Fluctuations

* **Close:** $749.33
* **Last-market:** $749.33 (change: 2.12)
* **5-day SMA:** $742.44
* **20-day SMA:** $771.23
* **60-day SMA:** $726.51


## Indicator Analysis
* **Market Risk Indicator (MRI):** 0.80
* **RSI:** 42.50
* **PPO:** -1.02
* **Hybrid Signal:** Buy (Cash 0%)
* **Risk Level:** Medium (MRI 0.80)
* **Recent (20 days) relative divergence change:** -8.10 (-): worsening
* **7-day Rank change:** 33 (+): rank up
* **7-day Dynamic Expected Return change:** -3.30 (-): worsening
* **Expected Return:** -48.00%


## Recent News & Significant Events
### 2026-01-21
* 40 teen scientists vie for $1.8M at Regeneron talent search - Stock Titan (news.google.com)
* YieldBoost REGN From 0.5% To 5.6% Using Options - Nasdaq (news.google.com)

### 2026-01-06
* REGN vs. ILMN: Which Stock Should Value Investors Buy Now? - Yahoo Finance (news.google.com)

### 2026-01-18
* Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Raised by Lmcg Investments LLC - MarketBeat (news.google.com)
* Does Regeneron (REGN) Prioritizing In‑House R&D Over Deals Recast Its Long‑Term Risk‑Reward Profile? - simplywall.st (news.google.com)

### 2026-01-02
* Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026 - Quiver Quantitative (news.google.com)


## Analyst Opinions
**Analyst Consensus:**
* **Key:** Buy
* **Mean (1=StrongBuy~5=Sell):** 1.69 (~Buy)
* **Opinions:** 26
* **Target Price (avg/high/low):** 825.23 / 1057.00 / 630.00


## Earnings Analysis
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-28 | 14.09 | 3.75 B$ |
| 2025-08-01 | 13.24 | 3.68 B$ |
| 2025-04-29 | 7.58 | 3.03 B$ |
| 2024-10-31 | 12.4 | 3.72 B$ |
| 2025-10-28 | 12.4 | 3.72 B$ |

## Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.75B | 86.11% |
| 2025-06-30 | $3.68B | 85.58% |
| 2025-03-31 | $3.03B | 84.67% |
| 2024-12-31 | $3.79B | 85.08% |
| 2024-09-30 | $3.72B | 86.80% |

## Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $30.96B | 4.72% |
| 2025-06-30 | $29.94B | 4.65% |
| 2025-03-31 | $29.39B | 2.75% |
| 2024-12-31 | $29.35B | 3.13% |
| 2024-09-30 | $29.33B | 4.57% |

## Comprehensive Analysis
Based on the analysis of the provided data, REGN has a higher cumulative return compared to S&P 500 (VOO) over the period. The stock's performance has been mostly positive in the long run, with some declines in certain periods. The hybrid signal is indicating a buy, while the risk level is medium due to the Market Risk Indicator (MRI) value. The recent news and significant events suggest that REGN is performing well, with potential for long-term growth.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.